Glido MP2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated for extended release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance and minimizing glycemic fluctuations. Glido MP2 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, liver function, and cardiovascular status is recommended during therapy. This combination therapy offers a multifaceted approach targeting insulin secretion, insulin resistance, and hepatic glucose output, thereby providing comprehensive management of hyperglycemia in type 2 diabetes.